Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Cel...
Guardado en:
Autores principales: | Melchiorre Cervello, Dimcho Bachvarov, Nadia Lampiasi, Antonella Cusimano, Antonina Azzolina, James A McCubrey, Giuseppe Montalto |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26c4e3428c444395a838e117dae31390 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
por: Izaque S Maciel, et al.
Publicado: (2013) -
Cytoplasmic vacuolation with endoplasmic reticulum stress directs sorafenib induced non-apoptotic cell death in hepatic stellate cells
por: Sachin Sharma, et al.
Publicado: (2021) -
Synergistic effects of 5-aminolevulinic acid based photodynamic therapy and celecoxib via oxidative stress in human cholangiocarcinoma cells
por: Kim CH, et al.
Publicado: (2013) -
Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein.
por: Stav Kemeny, et al.
Publicado: (2012) -
Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities
por: Srinuvasarao Rayavarapu, et al.
Publicado: (2017)